Kornimate/medical-research-clean huggingface dataset:
serum vegf as a tubal pregnancy marker

Conditions: Pregnancy, Ectopic

Summary: the aim of the present study was (i) to evaluate whether a single measurement of vegf would allow us to distinguish between intrauterine pregnancy (normal and abnormal) and ep and (ii) to correlate the levels of vegf with serum levels of progesterone and β-hcg in each subgroup. ninety patients were selected from a population of women presenting to the hospital das clínicas of the university of são paulo medical school from october 2006 until september 2007 and were divided in three subgroups: (i) abnormal (arrested) intrauterine pregnancy (defined as a gestational sac greater than 16 mm of mean diameter without fetal tissue or a embryo greater than 5 mm without embryo cardiac activity); (ii) tubal pregnancy (no evidence of intrauterine pregnancy, presence of a adnexal mass, suboptimal rise of serum hcg levels in 48 hours); all tubal pregnancies were surgically treated and were histologically confirmed, they did not receive any methotrexate treatment before operation; (iii) normal intrauterine pregnancy (intrauterine gestational sac, embryo vitality confirmed). blood samples were collected by peripheral venous puncture before treatment; a total 15 ml of blood was withdrawn (2 ml for β-hcg, 3ml for progesterone, 10 ml for vegf determinations). blood samples for vegf were collected in siliconized tubes and were allowed to coagulate at room temperature for 2-6 hours.


Eligibility criteria:
inclusion criteria were: * women that had a positive hcg test and presented with either abdominal pain or vaginal bleeding; all pregnancies were singletons, spontaneously conceived, with accurate assessments of their gestational age (42 - 56 days from the first day of the last menstrual period). a detailed informed consent was obtained from each patient before the inclusion. exclusion criteria was: * non-ampullar tubal pregnancy (surgically confirmed).

Keywords: pregnancy, ectopic vascular endothelial growth factor a pregnancy, tubal
external fixator or antibiotic-coated plate in severe open long bone fractures

Conditions: Fracture Related Infection

Summary: the purpose of the study is to assess whether infection rate is reduced with use of antibiotic-coated plate in severe open tibial fractures compare to use of external fixators


Eligibility criteria:
inclusion criteria: * age ≥ 18yrs, * gustilo-anderson iiia and iiib open fractures, * involvement of any long bone fractures that can be fixed with either plate or uniplanar external fixation, * wound can be closed primarily, with skin graft or flap, or can heal secondarily exclusion criteria: * patients with traumatic brain injury, * spinal cord injury, * severe burns, * 1 long bone fractures, * refusal to consent, * history of allergies to ceftriaxone or sulbactam, * fractures associated with vascular injury * and non-compliance with follow-up.
effectiveness of cervical screening in hpv vaccinated women

Conditions: Cervical Intraepithelial Neoplasia Grade 2/3

Summary: the main objective of the study is to identify whether or not being informed infrequently results about screening is: 1) at least as safe and accurate as frequently obtaining all information from the present combination of opportunistic/organized cervical screening by comparing regimen results of three screening visits at the ages of 22, 25 and 30 years (arm a1) vs. results of one screening visit at the age of 30 years (arm a2) in human papillomavirus (hpv) vaccinated young women.

altogether 16.500 1992-1995 born women vaccinated with the bi-valent human papillomavirus type 16 and 18 (hpv16/18) vaccine as adolescents either at the age of 12 to 15 or at the age of 18 will be invited to an effectiveness trial at the age of 22 years, and randomized into arms a1 and a2, and a3, respectively. cervical samples and cervico-vaginal self-samples rinsed in first-void urine will be analysed for hpv and c. trachomatis dna with mgp primer system followed by malditof mass spectrometry on the sequenom platform (hpv) and the abbott™ pcr (chlamydia trachomatis), respectively. with assumed \>50% participation the trial has 80% power to show non-inferiority of the infrequent vs. the frequent screening information. a one-way (participant) blinded interim analysis among the 1992-born study participants in a1 and a3 arms, who have attended the 2nd study visit at the age of 25 years, will be performed in 2017 for assuring no statistically significant differences in the cervical intraepithelial neoplasia grade 2/3 (cin2/cin3) incidences of the two arms. at the study end testing the null hypotheses of no difference in the incidence of the cin2/3 end-points between the a1 and a2 intervention arms will be done using the mantel-haenszel one degree of freedom chi-square statistics.

Eligibility criteria:
inclusion criteria: * hpv 16/18 vaccinated. born 1992-1995. exclusion criteria: * immunocompromising disease. hpv 6/11/16/18 vaccination.
asp 8825 - study in patients with painful diabetic polyneuropathy

Conditions: Diabetic Neuropathies

Summary: to demonstrate the superiority of asp8825 over placebo and dose response in patients with painful diabetic polyneuropathy.

three doses of asp8825 are compared to placebo in efficacy and safety point of view in patients with painful diabetic polyneuropathy.

Eligibility criteria:
inclusion criteria: * subjects aged 20 - 79 years * diabetes mellitus patients with diabetic polyneuropathy who have pain symptom for 26 weeks prior to the study * subjects who are compliant with diary completion exclusion criteria: * subjects who have pain from other diseases at the evaluating site * subjects who have nerve diseases at the evaluating site * subjects with foot ulcer or gangrene

Keywords: asp8825 diabetic neuropathies pain
a phase i study: pet imaging of cancer patients using [18f] 4-l-fluoroglutamine (2s,4r)

Conditions: Solid Malignancy; Lymphoma

Summary: this is a phase i study. this study is the first time that a new experimental drug called 18ffluoroglutamine, or f-glutamine, is being used in people. f-glutamine is a drug designed to be used with pet scanners that can 'see' where f-glutamine goes in the body, after its injected. pet scanners are one of the kinds of scanners you normally find in a hospital radiology department. the researchers have found that tumors in animals absorb f-glutamine. the researchers believe that scans with f-glutamine might be able to find tumors in patients. this first in-human study is being done to see how long f-glutamine lasts in the blood, when it is given to people in tiny amounts by an injection, and to see where f-glutamine goes in the body. if the results of this trial are good, then the study doctors plan to use f-glutamine in another trial to see if scans with f-glutamine are better for finding tumors compared to the standard types of scans that doctors use.


Eligibility criteria:
inclusion criteria: * patients with history of histologically-confirmed solid malignancy and/or lymphoma (histology confirmed by mskcc department of pathology.) disease measurable or evaluable as defined by recist 1.1 or other tumor response criteria from an mskcc irb-approved clinical research protocol. note: study patients do not need to be participating in an mskcc approved clinical trial prior to study recruitment. * age between 21-90 * negative serum pregnancy test for female patients of childbearing age and potential (as defined by mskcc standards \& guidelines), from assays obtained \<2 weeks prior to study enrollment. patients will be advised against having unprotected sexual intercourse from the time of the negative serum pregnancy test until after completing their participation in the study. exclusion criteria: * inability or refusal to have at least one peripheral intravenous line for intravenous access (as applicable to the day of \[18f\] 4-l-fluoroglutamine (2s,4r) injection and blood draws.) * breast-feeding * refusal or inability to tolerate the scanning procedure (e.g., due to claustrophobia) * hepatic: from assays obtained \<2 weeks prior to study enrollment for each patient, the upper limit of normal (uln) value for a particular assay will be defined by the normal reference values of the laboratory that performed the assay. * bilirubin \> 1.5 x (uln) * ast/alt \>2.5 x uln * albumin \< 3 g/dl * ggt \> 2.5 x uln if alkaline phosphatase \> 2.5 x uln. * renal: creatinine \>1.5 x uln or creatinine clearance \< 60 ml/min, from assays obtained \<2 weeks prior to study enrollment * acute major illness (e.g., unstable cardiovascular condition, etc.)

Keywords: pet imaging 18f] 4-l-fluoroglutam (2s,4r) 12-168
effect of urinary indwelling time on early continence after robot-assisted radical cystectomy with orthotopic ileal neobladder.

Conditions: Muscle-Invasive Bladder Carcinoma

Summary: the clinical trial assesses the effect of urinary indwelling time on early continence after robot- assisted radical cystectomy with orthotopic ileal neobladder.

radical cystectomy is the gold standard for muscle-invasive bladder. orthotopic ileal neobladder, as one of the urinary diversion methods, is preferred whenever possible to achieve a better postoperative quality of life. after surgery, the patient usually indwells a catheter until the anastomotic site heals. and the urinary indwelling time may have an effect on early continence. this is a prospective study including patients undergoing rarc with orthotopic ileal neobladder. urinary continence recovery and perioperative complication will be analyzed.

Eligibility criteria:
inclusion criteria: 1. patients with pathologically confirmed bladder cancer 2. undergoing robot-assisted radical cystectomy with orthotopic ileal neobladder 3. complete perioperative clinical data exclusion criteria: 1. patients diagnosed with distant metastasis 2. patients who had urinary incontinence before surgery 3. patients with unavailable follow-up data

Keywords: muscle-invasive bladder cancer robot-assisted radical cystectomy urinary indwelling time continence
low level laser treatment and breast cancer related lymphedema

Conditions: Lymphedema

Summary: manual lymphatic drainage (massage therapy) with compression (wearing a tight sleeve on the arm) is the current standard of treatment for breast cancer related lymphedema (arm swelling). low-level laser therapy (lllt) was approved in 2006 by the fda for professional and self/home treatment of lymphedema. lllt is being offered as a treatment option in many lymphedema treatment settings, but there are few studies of the effectiveness of lllt as a stand-alone lymphedema treatment or as a possible complementary lymphedema treatment modality to manual lymphatic drainage. the objective of this proposed pilot study is to examine the impact of advance practice nurse (anp) administered lllt, as both a stand-alone and complementary treatment, on arm volume, symptoms, and quality of life (qol) in breast cancer survivors with lymphedema. findings from this pilot study will be used to determine if lllt has possible value in the treatment of lymphedema and warrants subsequent evaluation in a larger study.

the purpose of this proposed pilot study is to examine the impact of advance practice nurse (anp) administered lllt, as both a stand-alone and complementary treatment, on arm volume, symptoms, and quality of life (qol) in breast cancer survivors with related le. findings from this pilot randomized study will be used to determine if lllt has possible value in the treatment of le and warrants subsequent evaluation in a larger study.

Eligibility criteria:
inclusion criteria: breast cancer survivors will be included if they: 1. are age 21 or older; 2. require professional treatment for stage i or ii lymphedema as defined by the international society of lymphology; 3. have an order for lymphedema treatment; and 4. are willing and able to drive to the study sites. exclusion criteria: individuals will not be included if they: 1. are actively undergoing intravenous chemotherapy or radiation therapy; 2. have a history of bilateral lymphedema that prohibits extracellular fluid comparison to an unaffected limb; 3. are unable to stand upright for measurement of height and weight; 4. have active/metastatic cancer; 5. are pregnant,: 6. have artificial joints in areas where electrode placement is critical, or have a pacemaker/internal defibrillator; or 7. have congestive heart failure (chf), chronic/acute renal or hepatic disease, pulmonary edema, thrombophlebitis, deep vein thrombosis (dvt), acute infection of any kind, and inflammation in the trunk or arms.

Keywords: lymphedema quality of life breast cancer symptoms lymphedema in breast cancer survivors
maltese antibiotic stewardship programme in the community (maspic): antibiotic prescribing for acute respiratory tract complaints

Conditions: Acute Respiratory Infection

Summary: antibiotic resistance has become a major threat to global public health. it is driven by a multitude of factors, however one of the leading factors is antibiotic prescribing. inappropriate antibiotic use and overuse of broad-spectrum antibiotics can lead to the development of resistant strains. since in malta the vast majority of antibiotics are acquired through prescription, targeting providers' prescribing behavior is an important strategy needed to try to curb antibiotic overuse and resistance. the aim of this study is to evaluate the effect of a multifaceted social marketing intervention in changing general practitioners' (gps) antibiotic prescribing behavior for patients with acute respiratory tract complaints in malta. this quasi-experimental intervention study using an interrupted time series design includes three phases; a formative pre-intervention phase, an intervention phase and post-intervention evaluation phase, and will last a total of four years. during the pre-intervention phase, various stakeholders, including gps, pharmacists and parents will be interviewed in order to get a better contextual understanding of antibiotic use in malta. a 1-year baseline surveillance system will also be set up to collect actual diagnosis-specific antibiotic prescribing by gp. this data will, at a later stage, be used to measure the change in antibiotic prescribing behavior post-intervention stage. gps stage of behavior change and intention to prescribe antibiotics will also be measure pre-intervention using questionnaires based on the theory of planned behavior and the transtheoretical model. the intervention stage will last 6 months and will include multiple components, including, delayed prescription pads, educational sessions, educational materials for patients and distribution of antibiotic guidelines. the intervention will be monitored closely through numerous process indicators. following the intervention, gps' stage of change and intention to prescribe antibiotics will be re-measured using the same questionnaire used pre-intervention. surveillance data collection will be also be resumed and will provide data to measure the primary outcome as well as additional secondary outcomes. the primary outcome of interest is the change in the rate of antibiotic prescribing for patients presenting with an acute respiratory tract complaint.


Eligibility criteria:
inclusion criteria: * all actively practicing general practitioners and trainees specializing within family medicine are eligible to participate regardless of whether they work on a part-time or full-time basis, or in the public and/or private sectors exclusion criteria: * general practitioners who are no longer actively working

Keywords: general practice social marketing behavior change antibiotic prescribing
exclusive enteral nutrition for remissionof crohn's diseases after surgery

Conditions: Crohn Disease in Remission

Summary: for patients with crohn's diseases undergoing surgery，whether postoperative exclusive enteral nutrition(een) could delay the endoscopic relapse needs exploration.the trial will investigate the efficacy of postoperative een for maintaining disease remission.


Eligibility criteria:
inclusion criteria: - cd patients who undergoing bowel resection with anastomosis exclusion criteria: * patients who received stoma creation
phenylephrine versus norepinephrine for septic shock in critically ill patients

Conditions: Septic Shock; Sepsis; Shock; Tachycardia; Arrhythmia

Summary: septic shock is a condition that is marked by severe infection causing hypotension requiring vasopressors to maintain adequate perfusion to vital organs. the surviving sepsis campaign, an international organization formed for the purpose of guiding the management of sepsis and septic shock, currently recommends norepinephrine as the first-choice vasopressor for septic shock. phenylephrine, a vasopressor fda-approved for use in septic shock, is recommended as an alternative vasopressor when septic shock is complicated by tachyarrhythmia to mitigate cardiac complications. this recommendation is based solely on experience with no scientific evidence to support this recommendation. the investigators will conduct an open-label randomized controlled trial (rct) directly comparing phenylephrine and norepinephrine, two fda-approved vasopressors that are both used in clinical practice for the management of septic shock. the investigators will perform this study with a population of patients that have septic shock to complete the following aims: aim 1: determine the incidence of tachyarrhythmias. aim 2: determine which vasopressor, phenylephrine or norepinephrine, is associated with a lower heart rate. aim 3: determine which vasopressor, phenylephrine or norepinephrine, is associated with a higher incidence of new tachyarrhythmias. aim 4: determine which vasopressor, phenylephrine or norepinephrine, is associated with less time in tachyarrhythmia. aim 5: determine which vasopressor, phenylephrine or norepinephrine, is associated with fewer complications, including cardiac complications. the investigators hypothesize that in this setting, phenylephrine will improve the management of septic shock when used as a "first choice" vasopressor by: 1. decreasing the mean heart rate 2. decreasing the incidence of new tachyarrhythmias 3. decreasing the amount of time spent in tachyarrhythmia for patients who develop new onset and recurrent tachyarrhythmias 4. decreasing the number of cardiac complications


Eligibility criteria:
inclusion criteria: * adults 18 years of age or greater * intention to treat with vasopressor for diagnosis of septic shock * exclusion criteria not met exclusion criteria: * emergent indication for surgery * patient possesses a terminal condition for which patient or medical decision maker has decided to de-escalate medical care (patients with do not resuscitate order but for whom standard care is continued will not be excluded) * known allergy to phenylephrine or norepinephrine * treated with vasopressor \>12 hours for current episode of shock * preference of specific vasopressor agent by patient's provider * pregnancy

Keywords: septic shock vasopressor agents phenylephrine norepinephrine tachycardia heart rate arrhythmia catecholamine
a trial of cranberry capsules for urinary tract infection prevention in nursing home residents

Conditions: Bacteriuria

Summary: urinary tract infection (uti) is the most common infection in nursing home residents, and bacteriuria is the greatest trigger for antimicrobial therapy in the nursing home setting. the primary aim of this study is to test the efficacy of two oral cranberry capsules per day in the reduction of bacteriuria plus pyuria in female nursing home residents. these aims will be accomplished by conducting a double blind randomized placebo controlled efficacy trial of two oral cranberry capsules daily versus placebo in a cohort of connecticut female nursing home residents.


Eligibility criteria:
inclusion criteria: 1. female residents; 2. long term residents 3. english speaking; and 4. age ≥ 65 years. exclusion criteria: 1. residents that are not expected to be in the nursing home for at least one month (i.e., short term rehabilitation, pending discharge, terminal \[life expectancy \< 1 month\]); 2. residents who are on chronic suppressive antibiotic or anti-infective (i.e., mandelamine) therapy for recurrent uti; 3. residents with end stage renal disease on dialysis (they do not regularly produce urine); 4. residents unable to produce a baseline clean catch urine specimen for collection; 5. residents on warfarin therapy because of a potential interaction of warfarin and cranberry juice; 6. residents with a history of nephrolithiasis because cranberry may increase the risk of nephrolithiasis; 7. have an indwelling bladder catheter in place; 8. have an allergy to cranberry products; 9. are being treated with cranberry products; 10. residence \<4 weeks.
development of multimodal fusion warning system and non-invasive techniques for early alzheimer's detection.

Conditions: Alzheimer's Disease

Summary: developing and validating an early digitalized recognition device and multimodal warning model for alzheimer's disease, and establishing a precision transcranial ultrasound stimulation intervention system.

1. establishment of early digitalized recognition devices and multimodal warning models for ad: participants undergo clinical assessments, and if they meet the inclusion criteria, their gender, age, mmse, moca, cdr, gds scores, as well as eeg erp and mr data are collected. eye-tracking analysis based on human-computer interaction perception technology, limb movement detection, and laser radar depth sensor fusion cognitive assessment are also performed simultaneously. after enrollment, follow-up assessments using scales (mmse, moca, cdr, gds, adas-cog, etc.) are conducted every six months, and eeg erp and mr data are collected annually. 2. construction of a precision transcranial ultrasound stimulation intervention system: participants were randomly divided into true stimulation group and false stimulation group: true/false stimulation for 2 weeks, washout for 2 weeks, false/true stimulation for 2 weeks. after treatment, behavioral scale assessment, eeg erp and multimodal mri were performed to evaluate the therapeutic effect.

Eligibility criteria:
inclusion criteria: 1. patients diagnosed with mci / ad 2. between the ages of 55 and 80 3. no history of mental illness such as schizophrenia, severe anxiety and depression exclusion criteria: 1. consistent with parkinson's disease, frontotemporal dementia, dementia with lewy bodies or huntington's disease diagnostic criteria 2. dementia due to other causes (e.g. cerebrovascular disease, central nervous system trauma, tumors, infections, metabolic diseases, normal stress hydrocephalus, folic acid or vitamin b12 deficiency, hypothyroidism, etc.) 3. have aphasia,disorders that affect cognitive assessment, such as disorders of consciousness 4. have a history of epilepsy or take antiepileptic drugs

Keywords: eeg mri digital intelligence equipment machine learning microstate